[go: up one dir, main page]

WO2005039534A8 - Lipophilic drug delivery vehicle and methods of use thereof - Google Patents

Lipophilic drug delivery vehicle and methods of use thereof

Info

Publication number
WO2005039534A8
WO2005039534A8 PCT/US2004/025412 US2004025412W WO2005039534A8 WO 2005039534 A8 WO2005039534 A8 WO 2005039534A8 US 2004025412 W US2004025412 W US 2004025412W WO 2005039534 A8 WO2005039534 A8 WO 2005039534A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
drug delivery
delivery vehicle
bioactive agent
lipophilic drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/025412
Other languages
French (fr)
Other versions
WO2005039534A1 (en
Inventor
Robert O Ryan
Michael N Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Oakland Research Center
Original Assignee
Childrens Hospital Oakland Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/004295 external-priority patent/WO2004073684A2/en
Application filed by Childrens Hospital Oakland Research Center filed Critical Childrens Hospital Oakland Research Center
Priority to JP2006533840A priority Critical patent/JP4786538B2/en
Priority to EP04780277A priority patent/EP1677763A1/en
Priority to AU2004283078A priority patent/AU2004283078A1/en
Priority to CA002541117A priority patent/CA2541117A1/en
Publication of WO2005039534A1 publication Critical patent/WO2005039534A1/en
Publication of WO2005039534A8 publication Critical patent/WO2005039534A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.
PCT/US2004/025412 2003-10-01 2004-08-06 Lipophilic drug delivery vehicle and methods of use thereof Ceased WO2005039534A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006533840A JP4786538B2 (en) 2003-10-01 2004-08-06 Lipophilic drug delivery vehicle and methods of use thereof
EP04780277A EP1677763A1 (en) 2003-10-01 2004-08-06 Lipophilic drug delivery vehicle and methods of use thereof
AU2004283078A AU2004283078A1 (en) 2003-10-01 2004-08-06 Lipophilic drug delivery vehicle and methods of use thereof
CA002541117A CA2541117A1 (en) 2003-10-01 2004-08-06 Lipophilic drug delivery vehicle and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50803503P 2003-10-01 2003-10-01
US60/508,035 2003-10-01
PCT/US2004/004295 WO2004073684A2 (en) 2003-02-14 2004-02-13 Lipophilic drug delivery vehicle and methods of use thereof
USPCT/US04/004295 2004-02-13

Publications (2)

Publication Number Publication Date
WO2005039534A1 WO2005039534A1 (en) 2005-05-06
WO2005039534A8 true WO2005039534A8 (en) 2005-09-09

Family

ID=34910664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/025412 Ceased WO2005039534A1 (en) 2003-10-01 2004-08-06 Lipophilic drug delivery vehicle and methods of use thereof

Country Status (5)

Country Link
EP (1) EP1677763A1 (en)
JP (2) JP4786538B2 (en)
AU (1) AU2004283078A1 (en)
CA (1) CA2541117A1 (en)
WO (1) WO2005039534A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884128B2 (en) 2012-12-18 2018-02-06 Jens Frauenfeld Salipro particles
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433693B (en) 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak Lipophilic drug delivery vehicle and methods of use thereof
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
GB0513096D0 (en) * 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
WO2007025719A1 (en) * 2005-08-29 2007-03-08 Technische Universitaet Muenchen Modified spider silk proteins
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
JP5781929B2 (en) * 2008-07-15 2015-09-24 ノバルティス アーゲー Immunogenic amphiphilic peptide composition
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
LT3043814T (en) 2013-09-13 2021-02-25 Salipro Biotech AB Antigen and method for production thereof
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
SG11201805594PA (en) * 2016-01-07 2018-07-30 Univ Western Health Sciences Formulations for treating bladder cancer
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2609399A1 (en) * 1987-01-13 1988-07-15 Ire Celltarg Sa PROCESS FOR INCORPORATING ONE OR MORE LIPOPHILIC ACTIVE INGREDIENTS INTO LIPOPROTEINS, LIPOPROTEINS OBTAINED AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
US5840707A (en) * 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
DE19640092A1 (en) * 1996-09-28 1998-04-16 Beiersdorf Ag Structures with lipid double membranes, in the lipophilic area of which longer-chain molecules are immersed or which are docked to such molecules through hydrophobic interactions
US6514523B1 (en) * 2000-02-14 2003-02-04 Ottawa Heart Institute Research Corporation Carrier particles for drug delivery and process for preparation
KR101111477B1 (en) * 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 A conjugate comprising cholesterol linked to a therapeutic agent
TWI433693B (en) * 2003-02-14 2014-04-11 Childrens Hosp & Res Ct Oak Lipophilic drug delivery vehicle and methods of use thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
US9884128B2 (en) 2012-12-18 2018-02-06 Jens Frauenfeld Salipro particles
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate

Also Published As

Publication number Publication date
JP2010248255A (en) 2010-11-04
AU2004283078A1 (en) 2005-05-06
JP4786538B2 (en) 2011-10-05
CA2541117A1 (en) 2005-05-06
JP2007526907A (en) 2007-09-20
WO2005039534A1 (en) 2005-05-06
EP1677763A1 (en) 2006-07-12

Similar Documents

Publication Publication Date Title
WO2004073684A3 (en) Lipophilic drug delivery vehicle and methods of use thereof
WO2005039534A8 (en) Lipophilic drug delivery vehicle and methods of use thereof
AU2002323151A1 (en) Application of lipid vehicles and use for drug delivery
WO2004026231A3 (en) Formulation for lipophilic agents
SI1345597T1 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
WO2006031878A3 (en) Imidazoquinoline compounds
WO2006073419A3 (en) Lipoprotein nanoplatforms
IL187277A (en) Foamable vehicle and pharmaceutical composition thereof
WO2004041247A3 (en) Geodate delivery vehicles
IL222880A (en) Peptides and uses thereof in the treatment and diagnosis of diseases and pharmaceutical compositions comprising the same
WO2004093795A3 (en) Compositions for delivery of drug combinations
WO2002067902A3 (en) Modulation of release from dry powder formulations
WO2006111524A3 (en) Il-21 variants
WO2005020958A3 (en) Aerosol delivery of curcumin
IL184065A (en) Tetrahydroquinoline analogues, uses thereof in the preparation of medicaments and pharmaceutical compositions comprising same
EP1420792A4 (en) Products and drug delivery vehicles
WO2007022239A3 (en) Pharmaceutical formulations for sustained drug delivery
WO2007117469A3 (en) Compositions of less immunogenic and long-circulating protein-lipid complexes
WO2005079867A3 (en) Alpha-emitting hydroxyapatite particles
WO2007044809A3 (en) Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
WO2008011272A3 (en) Liquid monophasic lipid-soluble antioxidant compositions and processes for making the compositions
WO2006028996A3 (en) Emulsan-alginate microspheres and methods of use thereof
SG118275A1 (en) Polymers for the delivery of bioactive agents and methods of their preparation
AU2001276831A1 (en) Delivery vehicle composition and methods for delivering antigens and other drugs
EP1292309A4 (en) Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 2006533840

Country of ref document: JP

Ref document number: 2541117

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 905/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004780277

Country of ref document: EP

Ref document number: 2004283078

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2004283078

Country of ref document: AU

Date of ref document: 20040806

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004283078

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004780277

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004780277

Country of ref document: EP